Search

Showing total 173 results
Start Over Topic breast cancer Topic estrogen receptor Publisher springer us
173 results

1. Estetrol and Mammary Gland: Friends or Foes?

Author

Vincent Wuidar, Anne Gallez, Christel Pequeux, Isabelle Dias Da Silva, and Jean-Michel Foidart

Subjects
Cancer Research, medicine.drug_class, Hormone Replacement Therapy, medicine.medical_treatment, Mammary gland, Estrogen receptor, Breast Neoplasms, Biology, Bioinformatics, Contraceptives, Oral, Hormonal, chemistry.chemical_compound, Breast cancer, medicine, Humans, Mammary Glands, Human, Review Paper, Estetrol, Hormone replacement therapy (menopause), medicine.disease, Menopause, medicine.anatomical_structure, Contraception, Oncology, chemistry, Estrogen, Female, Hormone therapy, hormones, hormone substitutes, and hormone antagonists
Abstract

Estrogens have pleiotropic effects on many reproductive and non-reproductive tissues and organs including the mammary gland, uterus, ovaries, vagina, and endothelium. Estrogen receptor α functions as the principal mediator of estrogenic action in most of these tissues. Estetrol (E4) is a native fetal estrogen with selective tissue actions that is currently approved for use as the estrogen component in a combined oral contraceptive and is being developed as a menopause hormone therapy (MHT, also known as hormone replacement therapy). However, exogenous hormonal treatments, in particular MHTs, have been shown to promote the growth of preexisting breast cancers and are associated with a variable risk of breast cancer depending on the treatment modality. Therefore, evaluating the safety of E4-based formulations on the breast forms a crucial part of the clinical development process. This review highlights preclinical and clinical studies that have assessed the effects of E4 and E4-progestogen combinations on the mammary gland and breast cancer, focusing in particular on the estrogenic and anti-estrogenic properties of E4. We discuss the potential advantages of E4 over current available estrogen-formulations as a contraceptive and for the treatment of symptoms due to menopause. We also consider the potential of E4 for the treatment of endocrine-resistant breast cancer.

Published
2021

5. Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration

Author

Lingyun Hu, Qi Zhu, Zheqi Li, Suchitra Kamle, Hema Negi, Zhenghua Wu, Guangwei Gao, Hao Chen, and Dawei Li

Subjects
medicine.medical_specialty, Leucine zipper, Cancer Research, MAP Kinase Signaling System, Proto-Oncogene Proteins c-jun, Estrogen receptor, AGR2, Breast Neoplasms, Biology, Breast cancer, Mucoproteins, Cell Movement, Internal medicine, Cell Line, Tumor, medicine, Humans, Insulin-Like Growth Factor I, Promoter Regions, Genetic, Transcription factor, Protein kinase B, Anterior gradient 2, Cell Proliferation, Oncogene Proteins, Original Paper, Leucine Zippers, Cell Cycle, Estrogen Receptor alpha, Activator protein-1 site, Genes, fos, Proteins, Estrogens, General Medicine, Hematology, medicine.disease, Endocrinology, Insulin-like growth factor-1, Oncology, Cancer research, MCF-7 Cells, Estrogen response element, Female, Signal transduction, Estrogen receptor alpha, Proto-Oncogene Proteins c-akt, Signal Transduction, Transcription Factors
Abstract

Anterior gradient 2 (AGR2) is a promising anti-tumor target associated with estrogen receptor expression and metastatic progression of breast cancer. Insulin-like growth factor-1 (IGF-1) is another potent factor that stimulates breast cancer progression and mediates anti-estrogen drug resistance. However, the precise mechanism and connections between these two factors in breast cancer drug resistance have not been fully elucidated. Here, for the first time, we decipher that IGF-1 remarkably induces AGR2 in the MCF7 cell line, through an estrogen response element (ERE) between −802 and −808 bp and a leucine zipper transcription factor-binding site located between −972 and −982 bp on the AGR2 promoter. We also found that the ERK1/2 and AKT pathways mediate estrogen receptor-α at the upstream of ERE and that the JNK pathway activates the leucine zipper site through the c-Jun/c-Fos complex. Additionally, our data suggest that knockdown of AGR2 reduces IGF-1-induced cell proliferation, migration and cell cycle progression. Therefore, we report that AGR2 is a key modulator involved in IGF-1-induced breast cancer development. We propose that the identification of the mechanism linking the IGF-1/insulin signal and AGR2 promoter activation is important, because it provides insights into the development of anti-breast cancer drugs.

Published
2015

14. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy

Author

Chaudhary, Lubna N., Jorns, Julie M., Sun, Yunguang, Cheng, Yee Chung, Kamaraju, Sailaja, Burfeind, John, Gonyo, Mary Beth, Kong, Amanda L., Patten, Caitlin, Yen, Tina, Cortina, Chandler S., Carson, Ebony, Johnson, Nedra, Bergom, Carmen, Tsaih, Shirng-Wern, Banerjee, Anjishnu, Wang, Yu, Chervoneva, Inna, Weil, Elizabeth, Chitambar, Christopher R., and Rui, Hallgeir

Published
2023
Full Text
View/download PDF

15. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Author

Sasada, Shinsuke, Kondo, Naoto, Hashimoto, Hiroya, Takahashi, Yuko, Terata, Kaori, Kida, Kumiko, Sagara, Yasuaki, Ueno, Takayuki, Anan, Keisei, Suto, Akihiko, Kanbayashi, Chizuko, Takahashi, Mina, Nakamura, Rikiya, Ishiba, Toshiyuki, Tsuneizumi, Michiko, Nishimura, Seiichiro, Naito, Yoichi, Hara, Fumikata, Shien, Tadahiko, and Iwata, Hiroji

Published
2023
Full Text
View/download PDF

34. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

Author

Lambertini, Matteo, Campbell, Christine, Gelber, Richard D., Viale, Giuseppe, McCullough, Ann, Hilbers, Florentine, Korde, Larissa A., Werner, Olena, Chumsri, Saranya, Jackisch, Christian, Wolff, Antonio C., Vaz-Luis, Ines, Ferreira, Arlindo R., Prat, Aleix, Moreno-Aspitia, Alvaro, Piccart, Martine, Loi, Sherene, and de Azambuja, Evandro

Published
2019
Full Text
View/download PDF

35. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention

Author

Walter, Katherine R., Ford, Marvella E., Gregoski, Mathew J., Kramer, Rita M., Knight, Kendrea D., Spruill, Laura, Nogueira, Lourdes M., Krisanits, Bradley A., Phan, Van, La Rue, Amanda C., Lilly, Michael B., Ambs, Stefan, Chan, King, Turner, Tonya F., Varner, Heidi, Singh, Shweta, Uribarri, Jaime, Garrett-Mayer, Elizabeth, Armeson, Kent E., Hilton, Ebony J., Clair, Mark J., Taylor, Marian H., Abbott, Andrea M., Findlay, Victoria J., Peterson, Lindsay L., Magwood, Gayenell, and Turner, David P.

Published
2019
Full Text
View/download PDF